Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hea-Eun | - |
dc.contributor.author | Lee, Min-Jeong | - |
dc.contributor.author | Kim, Woo-Sik | - |
dc.contributor.author | Jeong, Myung-Yung | - |
dc.contributor.author | Cho, Young-Sang | - |
dc.contributor.author | Choi, Guang Jin | - |
dc.date.accessioned | 2024-01-20T16:01:35Z | - |
dc.date.available | 2024-01-20T16:01:35Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2011-11-28 | - |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/129795 | - |
dc.description.abstract | PAT (process analytical technology) has been emphasized as one of key elements for the full implementation of QbD (quality-by-design) in the pharmaceutical area. NIRS (near-infrared spectroscopy) has been studied intensively as an in-line/on-line monitoring tool in chemical and biomedical industries. A precise and reliable monitoring of the particle characteristics during crystallization along with a suitable control strategy should be highly encouraged for the conformance to new quality system of pharmaceutical products. In this study, the anti-solvent crystallization process of indomethacin (IMC) was monitored using an in-line NIRS. IMC powders were produced via anti-solvent crystallization using two schemes; 'S-to-A' (solvent-to-antisolvent) and 'A-to-S' (antisolvent-to-solvent). In-line NIR spectra were analyzed by a PCA (principal component analysis) method. Although pure alpha-form IMC powder was resulted under A-to-S scheme, a mixture of the alpha-form and gamma-form was produced for S-to-A case. By integrating the PCA results with off-line characterization (SEM, XRD, DSC) data, the crystallization process under each scheme was elucidated by three distinct consecutive steps. It was demonstrated that in-line NIRS, combined with PCA, can be very useful to monitor in real time and interpret the anti-solvent crystallization process with respect to the polymorphism and particle size. (c) 2011 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | BENZOIC-ACID | - |
dc.subject | CRYSTALS | - |
dc.subject | TRANSFORMATION | - |
dc.subject | PRECIPITATION | - |
dc.subject | POLYMORPHISM | - |
dc.subject | MORPHOLOGY | - |
dc.subject | KINETICS | - |
dc.subject | FORMS | - |
dc.subject | SIZE | - |
dc.title | In-line monitoring and interpretation of an indomethacin anti-solvent crystallization process by near-infrared spectroscopy (NIRS) | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ijpharm.2011.08.044 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF PHARMACEUTICS, v.420, no.2, pp.274 - 281 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.citation.volume | 420 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 274 | - |
dc.citation.endPage | 281 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000303423800011 | - |
dc.identifier.scopusid | 2-s2.0-80054678656 | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | BENZOIC-ACID | - |
dc.subject.keywordPlus | CRYSTALS | - |
dc.subject.keywordPlus | TRANSFORMATION | - |
dc.subject.keywordPlus | PRECIPITATION | - |
dc.subject.keywordPlus | POLYMORPHISM | - |
dc.subject.keywordPlus | MORPHOLOGY | - |
dc.subject.keywordPlus | KINETICS | - |
dc.subject.keywordPlus | FORMS | - |
dc.subject.keywordPlus | SIZE | - |
dc.subject.keywordAuthor | Indomethacin (IMC) | - |
dc.subject.keywordAuthor | Polymorphism | - |
dc.subject.keywordAuthor | Anti-solvent crystallization | - |
dc.subject.keywordAuthor | Near-infrared spectroscopy (NIRS) | - |
dc.subject.keywordAuthor | Principal component analysis (PCA) | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.